medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-34-28-33medalphabet-4845Research ArticleСтатьиАнтитела, ассоциированные с воспалительными заболеваниями кишечника, при анкилозирующем спондилите: связь с клинико-лабораторными маркерами воспаленияInflammatory bowel disease-associated antibodies in ankylosing spondylitis: relationship with clinical and laboratory markers of inflammationhttps://orcid.org/0000-0003-4074-5907АлександроваЕ. Н.AleksandrovaE. A.

Александрова Елена Николаевна, д. м. н., зав. лабораторией клинической иммунологии

Москва

Aleksandrova Elena N., Dr Med Sci (habil.), head. Laboratory of Clinical Immunology

Moscow

aleksandrovaen2015@yandex.ruhttps://orcid.org/0000-0002-2738-2956НовиковА. А.NovikovA. A.

Новиков Александр Александрович, д. б. н., ведущий научный сотрудник лаборатории клинической иммунологии, доцент кафедры клинической лабораторной диагностики

Москва

Novikov Alexander A., Dr Bio Sci (habil.), leading researcher at the Laboratory of Clinical Immunology, Associate Professor of the Department of Clinical Laboratory Diagnostics

Moscow

https://orcid.org/0000-0003-3747-9644КулаковаП. И.KulakovaP. I.

Кулакова Полина Игоревна, врач-ревматолог отделения ревматологии

Москва

Kulakova Polina I., rheumatologist at Dept of Rheumatology

Moscow

https://orcid.org/0000-0002-5202-4878КольцоваЕ. Н.KoltsovaE. N.

Кольцова Екатерина Николаевна, к. м. н., зав. отделом медицинской онкологии и клинической эндоскопии и рентгенологии 21 (ОМО и КЭР 21)

Москва

Koltsova Ekaterina N., PhD Med, head of Dept of Medical Oncology and Clinical Endoscopy and Radiology 21 (OMO and CER 21)

Moscow

https://orcid.org/0000-0002-3674-8518БорисоваМ. А.BorisovaM. A.

Борисова Мария Александровна, к. м. н., старший научный сотрудник отдела ревматологии

Москва

Borisova Maria A., PhD Med, senior researcher at Dept of Rheumatology

Moscow

https://orcid.org/0000-0001-7958-5926ЛукинаГ. В.LukinaG. V.

Лукина Галина Викторовна, д. м. н., профессор, заведующая отделом ревматологии, ведущий научный сотрудник

Москва

Lukina Galina V., Dr Med Sci (habil.), professor, head of Dept of Rheumatology, leading researcher

Moscow

ГБУЗ города Москвы «Московский клинический научно-практический центр имени А. С. Логинова Департамента здравоохранения города Москвы»РоссияA. S. Loginov Moscow Clinical Scientific CenterRussian FederationГБУЗ города Москвы «Московский клинический научно-практический центр имени А. С. Логинова Департамента здравоохранения города Москвы»; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России (Пироговский университет)РоссияA. S. Loginov Moscow Clinical Scientific Center; N. I. Pirogov Russian National Research Medical UniversityRussian FederationГБУЗ города Москвы «Московский клинический научно-практический центр имени А. С. Логинова Департамента здравоохранения города Москвы»; ФГБНУ «Научно-исследовательский институт ревматологии им. В. А. Насоновой»РоссияA. S. Loginov Moscow Clinical Scientific Center; V. A. Nasonova Research Institute of RheumatologyRussian Federation202527012026134«Гастроэнтерология и диетология» (4)2833Copyright © Александрова Е.Н., Новиков А.А., Кулакова П.И., Кольцова Е.Н., Борисова М.А., Лукина Г.В., 20262026Александрова Е.Н., Новиков А.А., Кулакова П.И., Кольцова Е.Н., Борисова М.А., Лукина Г.В.Aleksandrova E.A., Novikov A.A., Kulakova P.I., Koltsova E.N., Borisova M.A., Lukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4845Цель

Цель. Изучить взаимосвязь уровней антител, ассоциированных с воспалительными заболеваниями кишечника (ВЗК), и маркеров воспаления при анкилозирующем спондилите (АС).

Материалы и методы

Материалы и методы. Исследованы сыворотки 44 здоровых доноров (ЗД) и 51 больных АС: 40 мужчин, 11 женщин в возрасте 44,0 (34,0–49,0) лет с длительностью заболевания 12,0 (5,0–20,0) лет, высокой активностью болезни (BASDAI – 5,3; 4,5–6,4; ASDAS СОЭ – 3,6; 3,0–4,4; ASDAS СРБ – 3,7; 2,8–4,5). У 22 % больных АС были диагностированы ВЗК. IgG/IgA антитела к S. cerevisiae (ASCA), IgG/IgA антитела к гликопротеину 2 (аGP2), IgG антитела к катепсину G, эластазе, сывороточный кальпротектин (сКП), интерлейкин-6 (IL-6) определяли иммуноферментным методом.

Результаты

Результаты. Больные АС без ВЗК и АС с ВЗК имели более высокие уровни IgA ASCA, IgA аGP2, антител к эластазе, чем ЗД (4,5; 2,6–6,4 ЕД/мл и 4,9; 3,7–7,3 ЕД/мл vs 1,9; 0,6–2,6 ЕД/мл, р=0,0008, р=0,001; 1,2; 0,8–5,5 ЕД/мл и 1,2; 0,9–11,8 ЕД/мл vs 0,7; р=0,007, р=0,02; 8,2; 5,9–9,9 ЕД/мл и 9,1; 8,5–10,5 ЕД/мл vs 5,6; 4,7–8,3 ЕД/мл, р=0,01, р=0,003). Концентрация антител к катепсину G была выше при АС с ВЗК по сравнению с АС без ВЗК (0,8; 0,5–1,0 ЕД/мл vs 0,4; 0,3–0,6 ЕД/мл, р=0,02). Уровни IgA ASCA коррелировали с IL-6 (r=0,3), IgA аGP2 – с сКП (r=0,3), антител к эластазе – с СОЭ (r=0,4), антител к катепсину G – с СОЭ (r=0,4) и BASDAI (r=0,4) (p<0,05).

Заключение

Заключение. Повышение уровней IgA ASCA, IgA аGP2 и антител к эластазе при АС без ВЗК сходно с таковым при АС с ВЗК. Гиперпродукция IgA ASCA, IgA аGP2, антител к эластазе, катепсину G отражает воспалительную активность АС.

Background/Purpose

Background/Purpose. To study the relationship between levels of antibodies associated with inflammatory bowel diseases (IBD) and inflammatory markers in ankylosing spondylitis (AS).

Materials and methods

Materials and methods. The sera of 44 healthy donors (HD) and 51 patients with AS were studied: 40 men, 11 women aged 44.0 (34.0–49.0) years with a disease duration of 12.0 (5.0–20.0) years, high disease activity (BASDAI – 5.3; 4.5–6.4; ASDAS ESR – 3.6; 3.0–4.4; ASDAS CRP – 3.7; 2.8–4.5). IBD was diagnosed in 22 % of patients with AS. IgG/IgA antibodies to S. cerevisiae (ASCA), IgG/IgA antibodies to glycoprotein 2 (GP2), IgG antibodies to cathepsin G, elastase, serum calprotectin (sCP), interleukin-6 (IL-6) were determined by ELISA.

Results

Results. Patients with AS without IBD and AS with IBD had higher levels of IgA ASCA, IgA aGP2, and elastase antibodies than HD (4.5; 2.6–6.4 U/ml and 4.9; 3.7–7.3 U/ml vs 1.9; 0.6–2.6 U/ml, p=0.0008, p=0.001; 1.2; 0.8–5.5 U/ml and 1.2; 0.9–11.8 U/ml vs 0.7; p=0.007, p=0.02; 8.2; 5.9–9.9 U/ml and 9.1; 8.5–10.5 U/ml vs 5.6; 4.7–8.3 U/ml, p=0.01, p=0.003). The concentration of antibodies to cathepsin G was higher in AS with IBD compared to AS without IBD (0.8; 0.5–1.0 U/ml vs 0.4; 0.3–0.6 U/ml, p=0.02). The levels of IgA ASCA correlated with IL-6 (r=0.3), IgA aGP2 – with sCP (r=0.3), antibodies to elastase – with ESR (r=0.4), antibodies to cathepsin G – with ESR (r=0.4) and BASDAI (r=0.4) (p<0.05).

Conclusion

Conclusion. Elevated levels of IgA ASCA, IgA aGP2, and anti-elastase antibodies in AS without IBD are similar to those in AS with IBD. Hyperproduction of IgA ASCA, IgA aGP2, anti-elastase antibodies, and cathepsin G reflects the inflammatory activity of AS.

анкилозирующий спондилитвоспалительные заболевания кишечникаантитела к S. cerevisiae (ASCA)гликопротеину 2катепсину GэластазеBASDAIСОЭсывороточный кальпротектининтерлейкин-6ankylosing spondylitisinflammatory bowel diseasesantibodies to S. cerevisiae (ASCA)glycoprotein 2cathepsin GelastaseBASDAIESRserum calprotectininterleukin-6ReferencesЭрдес Ш. Ф. Анкилозирующий спондилит. В кн.: Насонов Е. Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа, 2019: 58–86.Erdes Sh. F. Ankylosing spondylitis. In: Nasonov E. L., ed. Russian Clinical Guidelines. Rheumatology. [Rossiyskie Klinicheskie Rekomendatsii. Revmatologiya.]. Moscow: GEOTAR-Media, 2019: 58–86. (In Russ.).Harbord M., Annese V., Vavricka S. R., Allez M., Barreiro-de Acosta M., Boberg K. M. et al.; European Crohn’s and Colitis Organisation. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016; 10 (3): 239–54. https://doi.org/10.1093/ecco-jcc/jjv213Harbord M., Annese V., Vavricka S. R., Allez M., Barreiro-de Acosta M., Boberg K. M. et al.; European Crohn’s and Colitis Organisation. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016; 10 (3): 239–54. https://doi.org/10.1093/ecco-jcc/jjv213Stolwijk C., van Tubergen A., Castillo-Ortiz J.D., Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74 (1): 65–73. https://doi.org/10.1136/annrheumdis-2013-203582Stolwijk C., van Tubergen A., Castillo-Ortiz J.D., Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74 (1): 65–73. https://doi.org/10.1136/annrheumdis-2013-203582Benfaremo D., Luchetti M. M., Gabrielli A. Biomarkers in inflammatory bowel disease-associated spondyloarthritis: state of the art and unmet needs. J Immunol Res. 2019; 2019: 8630871. https://doi.org/10.1155/2019/8630871Benfaremo D., Luchetti M. M., Gabrielli A. Biomarkers in inflammatory bowel disease-associated spondyloarthritis: state of the art and unmet needs. J Immunol Res. 2019; 2019: 8630871. https://doi.org/10.1155/2019/8630871Karreman M. C., Luime J. J., Hazes J. M.W., Weel A. E.A.M. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017; 11 (5): 631–42. https://doi.org/ 10.1093/ ecco-jcc/jjw199Karreman M. C., Luime J. J., Hazes J. M.W., Weel A. E.A.M. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017; 11 (5): 631–42. https://doi.org/ 10.1093/ ecco-jcc/jjw199van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27 (4): 361–8. https://doi.org/10.1002/art.1780270401van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27 (4): 361–8. https://doi.org/10.1002/art.1780270401Prideaux L., De Cruz P., Ng S. C., Kamm M. A. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012; 18 (7): 1340–55. https://doi.org/10.1002/ibd.21903Prideaux L., De Cruz P., Ng S. C., Kamm M. A. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012; 18 (7): 1340–55. https://doi.org/10.1002/ibd.21903Александрова Е. Н., Новиков А. А., Лукина Г. В., Парфенов А. И. Клиническое значение антител при воспалительных заболеваниях кишечника. Терапевтический архив. 2021; 93 (2): 103–10.Aleksandrova E. N., Novikov A. A., Lukina G. V., Parfenov A. I. Clinical value of antibodies in inflammatory bowel diseases. Terapevticheskiy Arkhiv. 2021; 93 (2): 103–10. (In Russ.). https://doi.org/10.26442/00403660.2021.02.200610Mitsuyama K., Niwa M., Takedatsu H., Yamasaki H., Kuwaki K., Yoshioka S. et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016; 22 (3): 1304–10. https://doi.org/10.3748/wjg.v22.i3.1304Mitsuyama K., Niwa M., Takedatsu H., Yamasaki H., Kuwaki K., Yoshioka S. et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016; 22 (3): 1304–10. https://doi.org/10.3748/wjg.v22.i3.1304Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006; 52 (2): 171–81. https://doi.org/10.1373/clinchem.2005.058560Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006; 52 (2): 171–81. https://doi.org/10.1373/clinchem.2005.058560Kuna A. T. Serological markers of inflammatory bowel disease. Biochem Med. (Zagreb). 2013; 23 (1): 28–42. https://doi.org/10.11613/bm.2013.006Kuna A. T. Serological markers of inflammatory bowel disease. Biochem Med. (Zagreb). 2013; 23 (1): 28–42. https://doi.org/10.11613/bm.2013.006Bonneau J., Dumestre-Perard C., Rinaudo-Gaujous M., Genin C., Sparrow M., Roblin X., Paul S. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM–CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015; 14 (3): 231–45. https://doi.org/10.1016/j.autrev.2014.11.004Bonneau J., Dumestre-Perard C., Rinaudo-Gaujous M., Genin C., Sparrow M., Roblin X., Paul S. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM–CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015; 14 (3): 231–45. https://doi.org/10.1016/j.autrev.2014.11.004Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010; 122 (4): 177–85. https://doi.org/10.3810/pgm.2010.07.2184Arai R. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. Postgrad Med. 2010; 122 (4): 177–85. https://doi.org/10.3810/pgm.2010.07.2184Hoffman I. E., Demetter P., Peeters M., De Vos M., Mielants H., Veys E. M., De Keyser F. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003; 62 (5): 455–9. https://doi.org/10.1136/ard.62.5.455Hoffman I. E., Demetter P., Peeters M., De Vos M., Mielants H., Veys E. M., De Keyser F. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003; 62 (5): 455–9. https://doi.org/10.1136/ard.62.5.455De Vries M., van der Horst-Bruinsma I., van Hoogstraten I., van Bodegraven A., von Blomberg B. M., Ratnawati H., Dijkmans B. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol. 2010; 37 (11): 2340–4. https://doi.org/10.3899/jrheum.100269De Vries M., van der Horst-Bruinsma I., van Hoogstraten I., van Bodegraven A., von Blomberg B. M., Ratnawati H., Dijkmans B. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol. 2010; 37 (11): 2340–4. https://doi.org/10.3899/jrheum.100269Wallis D., Asaduzzaman A., Weisman M., Haroon N., Anton A., McGovern D., Targan S, Inman R. Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. Arthritis Res Ther. 2013; 15 (5): R 166. https://doi.org/10.1186/ar4350Wallis D., Asaduzzaman A., Weisman M., Haroon N., Anton A., McGovern D., Targan S, Inman R. Elevated serum anti-flagellin antibodies implicate subclinical bowel inflammation in ankylosing spondylitis: an observational study. Arthritis Res Ther. 2013; 15 (5): R 166. https://doi.org/10.1186/ar4350Török H. P., Glas J., Gruber R., Brumberger V., Strasser C., Kellner H. et al. Inflammatory bowel disease-specific autoantibodies in HLA-B 27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion. 2004; 70 (1): 49–54. https://doi.org/10.1159/000080081Török H. P., Glas J., Gruber R., Brumberger V., Strasser C., Kellner H. et al. Inflammatory bowel disease-specific autoantibodies in HLA-B 27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion. 2004; 70 (1): 49–54. https://doi.org/10.1159/000080081Aydin S. Z., Atagunduz P., Temel M., Bicakcigil M., Tasan D., Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford). 2008; 47 (2): 142–4. https://doi.org/10.1093/rheumatology/kem324Aydin S. Z., Atagunduz P., Temel M., Bicakcigil M., Tasan D., Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford). 2008; 47 (2): 142–4. https://doi.org/10.1093/rheumatology/kem324Riente L., Chimenti D., Pratesi F., Delle Sedie A., Tommasi S., Tommasi C., Bombardieri S., Migliorini P. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol. 2004; 31 (5): 920–4.Riente L., Chimenti D., Pratesi F., Delle Sedie A., Tommasi S., Tommasi C., Bombardieri S., Migliorini P. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol. 2004; 31 (5): 920–4.Matzkies F. G., Targan S. R., Berel D., Landers C. J., Reveille J. D., McGovern D.P., Weisman M. H. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Ther. 2012; 14 (6): R 261. https://doi.org/10.1186/ar4106Matzkies F. G., Targan S. R., Berel D., Landers C. J., Reveille J. D., McGovern D.P., Weisman M. H. Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Ther. 2012; 14 (6): R 261. https://doi.org/10.1186/ar4106Romero-Sánchez C., Bautista-Molano W., Parra V., De Avila J., Rueda J. C., Bello-Gualtero J.M., Londoño J., Valle-Oñate R. Gastrointestinal symptoms and elevated levels of anti-Saccharomyces cerevisiae antibodies are associated with higher disease activity in Colombian patients with spondyloarthritis. Int J Rheumatol. 2017; 2017: 4029584. https://doi.org/10.1155/2017/4029584Romero-Sánchez C., Bautista-Molano W., Parra V., De Avila J., Rueda J. C., Bello-Gualtero J.M., Londoño J., Valle-Oñate R. Gastrointestinal symptoms and elevated levels of anti-Saccharomyces cerevisiae antibodies are associated with higher disease activity in Colombian patients with spondyloarthritis. Int J Rheumatol. 2017; 2017: 4029584. https://doi.org/10.1155/2017/4029584Mundwiler M. L., Mei L., Landers C. J., Reveille J. D., Targan S., Weisman M. H. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthritis Res Ther. 2009; 11 (6): R 177. https://doi.org/10.1186/ar2866Mundwiler M. L., Mei L., Landers C. J., Reveille J. D., Targan S., Weisman M. H. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study. Arthritis Res Ther. 2009; 11 (6): R 177. https://doi.org/10.1186/ar2866Александрова Е. Н., Новиков А. А., Насонов Е. Л. Лабораторная диагностика ревматических заболеваний. В кн.: Насонов Е. Л., ред. Российские клинические рекомендации. Ревматология. М.: ГЭОТАР-Медиа, 2019: 302–20.Aleksandrova E. N., Novikov A. A., Nasonov E. L. Laboratory diagnosis of rheumatic diseases. In: Nasonov E. L., ed. Russian Clinical Guidelines. Rheumatology. Rossiyskie Klinicheskie Rekomendatsii. Revmatologiya. Moscow: GEOTAR-Media, 2019: 302–20. (In Russ.).Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. 2022; 63 (2): 124–37. https://doi.org/10.1007/s12016-021-08888-9Terziroli Beretta-Piccoli B., Mieli-Vergani G., Vergani D. Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. 2022; 63 (2): 124–37. https://doi.org/10.1007/s12016-021-08888-9Tornai D., Ven P. L., Lakatos P. L., Papp M. Serological biomarkers for management of primary sclerosing cholangitis. World J Gastroenterol. 2022; 28 (21): 2291–2301. https://doi.org/10.3748/wjg.v28.i21.2291Tornai D., Ven P. L., Lakatos P. L., Papp M. Serological biomarkers for management of primary sclerosing cholangitis. World J Gastroenterol. 2022; 28 (21): 2291–2301. https://doi.org/10.3748/wjg.v28.i21.2291Kyriakidi K. S., Tsianos V. E., Karvounis E., Christodoulou D. K., Katsanos K. H., Tsianos E. V.. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. Ann Gastroenterol. 2016; 29 (3): 258–67. https://doi.org/10.20524/aog.2016.0028Kyriakidi K. S., Tsianos V. E., Karvounis E., Christodoulou D. K., Katsanos K. H., Tsianos E. V.. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. Ann Gastroenterol. 2016; 29 (3): 258–67. https://doi.org/10.20524/aog.2016.0028Lindgren S., Nilsson S., Nässberger L., Verbaan H., Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol. 2000; 15 (4): 437–42. https://doi.org/10.1046/j.1440-1746.2000.02078.xLindgren S., Nilsson S., Nässberger L., Verbaan H., Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol. 2000; 15 (4): 437–42. https://doi.org/10.1046/j.1440-1746.2000.02078.xАлександрова Е. Н., Новиков А. А., Кулакова П. И., Кольцова Е. Н., Савенкова Н. А., Волнухин Е. В., Ковшик А. Н., Лукина Г. В. Антитела, ассоциированные с воспалительными заболеваниями кишечника, при анкилозирующем спондилите. Клиническая лабораторная диагностика. 2025; 70 (2): 112–118.Aleksandrova E. N., Novikov A. A., Kulakova P. I., Koltsova Е. N., Savenkova N. A., Volnukhin E. V., Kovschik A. N., Lukina G. V. Antibodies associated with inflammatory bowel diseases in ankylosing spondylitis. Klinicheskaya Laboratornaya Diagnostika (Russian Clinical Laboratory Diagnostics). 2025; 70 (2): 112–118. (In Russ.). https://doi.org/10.51620/0869-2084-2025-70-2-112-118Александрова Е. Н., Новиков А. А. Лабораторные биомаркеры анкилозирующего спондилита. Научно-практическая ревматология. 2017; 55 (1): 96–103.Aleksandrova E. N., Novikov A. A. Laboratory biomarkers for ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017; 55 (1): 96–103. (In Russ.). http://dx.doi.org/10.14412/1995-4484-2017-96-103Rudwaleit M., Haibel H., Baraliakos X., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009; 60 (3): 717–27. http://dx.doi.org/10.1002/art.24483Rudwaleit M., Haibel H., Baraliakos X., Listing J., Märker-Hermann E., Zeidler H., Braun J., Sieper J. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009; 60 (3): 717–27. http://dx.doi.org/10.1002/art.24483Vogl T., Tenbrock K., Ludvig S., Leukert N., Ehrhardt C., van Zoelen M. A., Nacken W., Foell D., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxine-induced shock. Nat Med. 2007; 13: 1042–9. http://dx.doi.org/10.1038/nm1638Vogl T., Tenbrock K., Ludvig S., Leukert N., Ehrhardt C., van Zoelen M. A., Nacken W., Foell D., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxine-induced shock. Nat Med. 2007; 13: 1042–9. http://dx.doi.org/10.1038/nm1638Turina M. C., Yeremenko N., Paramarta J. E., De Rycke L., Baeten D. Calprotectin (S 100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014; 16 (4): 413. http://dx.doi.org/10.1186/s13075-014-0413-4Turina M. C., Yeremenko N., Paramarta J. E., De Rycke L., Baeten D. Calprotectin (S 100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014; 16 (4): 413. http://dx.doi.org/10.1186/s13075-014-0413-4Cypers H., Varkas G., Beeckman S., Debusschere K., Vogl T., Roth J., Drennan M. B., Lavric M., et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016; 75 (7): 1357–62. http://dx.doi.org/10.1136/annrheumdis-2015–208025Cypers H., Varkas G., Beeckman S., Debusschere K., Vogl T., Roth J., Drennan M. B., Lavric M., et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016; 75 (7): 1357–62. http://dx.doi.org/10.1136/annrheumdis-2015–208025Oktayoglu P., Bozkurt M., Mete N., Caglayan M., Em S., Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014; 62 (6): 880–4. https://doi.org/10.1097/JIM.0000000000000095Oktayoglu P., Bozkurt M., Mete N., Caglayan M., Em S., Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014; 62 (6): 880–4. https://doi.org/10.1097/JIM.0000000000000095Лукина Г. В., Кулакова П. И., Новиков А. А., Александрова Е. Н., Савенкова Н. А., Волнухин Е. В., Ковшик А. Н., Климец А. Г. Место сывороточного кальпротектина в диагностике воспалительных заболеваний кишечника у пациентов с анкилозирующим спондилитом (предварительные результаты). Медицинский алфавит. 2021; (33): 16–19.Lukina G. V., Kulakova P. I., Novikov A. A., Alexandrova E. N., Savenkova N. A., Volnukhin E. V., Kovshik A. N., Klimets A. G. Role of serum calprotectin in diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitis (preliminary results). Medical alphabet. 2021; (33): 16–19. (In Russ.). https://doi.org/10.33667/2078-5631-2021Klingberg E., Strid H., Ståhl A., Deminger A., Carlsten H., Öhman L., Forsblad-d'Elia H. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017; 19 (1): 21. https://doi.org/10.1186/s13075-017-1223-2Klingberg E., Strid H., Ståhl A., Deminger A., Carlsten H., Öhman L., Forsblad-d'Elia H. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017; 19 (1): 21. https://doi.org/10.1186/s13075-017-1223-2Лукина Г. В., Кулакова П. И., Новиков А. А., Александрова Е. Н., Савенкова Н. А., Волнухин Е. В., Ковшик А. Н. Частота развития воспалительных заболеваний кишечника у пациентов с анкилозирующим спондилитом (предварительные результаты исследования). Медицинский алфавит. 2019; 37: 12–15.Lukina G. V., Kulakova P. I., Novikov A. A., Alexandrova E. N., Savenkova N. A., Volnukhin E. V., Kovshik A. N. Incidence of inflammatory bowel disease in patients with ankylosing spondylitis (preliminary study results). Medical alphabet. 2019; 37: 12–15. (In Russ.). https://doi.org/10.33667/2078-5631-2019-2-37(412)-12-15Prajzlerová K., Grobelná K., Pavelka K., Šenolt L., Filková M. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016; 15 (6): 501–9. https://doi.org/10.1016/j.autrev.2016.02.002Prajzlerová K., Grobelná K., Pavelka K., Šenolt L., Filková M. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016; 15 (6): 501–9. https://doi.org/10.1016/j.autrev.2016.02.002Reveille J. D. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015; 34 (6): 1009–18. https://doi.org/10.1007/s10067-015-2949-3Reveille J. D. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015; 34 (6): 1009–18. https://doi.org/10.1007/s10067-015-2949-3Gratacós J., Collado A., Filella X., Sanmartí R., Cañete J., Llena J., Molina R., Ballesta A., Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994; 33 (10): 927–31. https://doi.org/10.1093/rheumatology/33.10.927Gratacós J., Collado A., Filella X., Sanmartí R., Cañete J., Llena J., Molina R., Ballesta A., Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994; 33 (10): 927–31. https://doi.org/10.1093/rheumatology/33.10.927Dmowska-Chalaba J., Kontny E. Inflammatory bowel disease-related arthritis – clinical evaluation and possible role of cytokines. Reumatologia. 2015; 53 (5): 236–42. https://doi.org/10.5114/reum.2015.55824Dmowska-Chalaba J., Kontny E. Inflammatory bowel disease-related arthritis – clinical evaluation and possible role of cytokines. Reumatologia. 2015; 53 (5): 236–42. https://doi.org/10.5114/reum.2015.55824

The authors declare that there are no conflicts of interest present.